{
    "organizations": [],
    "uuid": "adc11128d24fb9d13910dc04d7f919624a228dc1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pharma-mar-says-phase-iii-trial-wi/brief-pharma-mar-says-phase-iii-trial-with-zepsyre-in-resistant-ovarian-cancer-not-met-its-primary-endpoint-idUSFWN1PD1E8",
    "ord_in_thread": 0,
    "title": "BRIEF-Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 18 (Reuters) - PHARMA MAR SA:\n* CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT Source text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-19T02:09:00.000+02:00",
    "crawled": "2018-01-19T12:29:26.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "pharma",
        "mar",
        "sa",
        "corail",
        "phase",
        "iii",
        "zepsyre",
        "resistant",
        "ovarian",
        "cancer",
        "met",
        "primary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}